NEUT-SFL in Patients with COVID-ARDS: A Novel Biomarker for Thrombotic Events?

Laure Stiel(Inserm), Khaldoun Kuteifan(Groupe Hospitalier de la Région de Mulhouse et Sud Alsace), Yannick Rabouël(Groupe Hospitalier de la Région de Mulhouse et Sud Alsace), Valentin Pointurier(Groupe Hospitalier de la Région de Mulhouse et Sud Alsace), Agathe Debliquis(Groupe Hospitalier de la Région de Mulhouse et Sud Alsace), Joy Mootien(Centre Hospitalier de Mulhouse)
Disease Markers
November 17, 2021
10.1155/2021/4361844
Cited by 5

Related Papers

Discrepancies between Perceptions by Physicians and Nursing Staff of Intensive Care Unit End-of-Life Decisions
|American Journal of Respiratory and Critical Care Medicine|2003|311
Clinical characteristics and risk factors associated with severe COVID-19: prospective analysis of 1,045 hospitalised cases in North-Eastern France, March 2020
|Eurosurveillance|2020|129
Identification of driver genes for critical forms of COVID-19 in a deeply phenotyped young patient cohort
|Science Translational Medicine|2021|125
An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19
|Clinical Microbiology and Infection|2021|107
Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial
|Critical Care|2023|47